Literature DB >> 22911282

Thyroid nodules in acromegaly.

Amelia Rogozinski1, Alejandra Furioso, Patricia Glikman, Marcelo Junco, Rosa Laudi, Adriana Reyes, Alicia Lowenstein.   

Abstract

OBJECTIVE: We made a prospective study evaluating the prevalence of thyroid nodular disease in acromegalic patients. SUBJECTS AND METHODS: Thyroid ultrasound and ultrasound-guided fine needle aspiration biopsy were performed when nodules were detected. Nodules were characterized by cytology and histopathology.
RESULTS: We found high prevalence of nodular thyroid disorder, 23/34 (67%) in acromegalic patients. High risk and malignant cytology were significantly higher in acromegalic patients than in our non-acromegalic population (25% vs. 9%). Differentiated thyroid carcinoma was present in 11% of the acromegalic patients.
CONCLUSIONS: We strongly recommend periodic thyroid evaluation by ultrasound in patients with acromegaly. Fine needle aspiration biopsy should be performed in nodules larger than 10 mm, and in all suspicious nodules, regardless of the size.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22911282     DOI: 10.1590/s0004-27302012000500004

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  10 in total

Review 1.  Acromegaly: clinical features at diagnosis.

Authors:  Lucio Vilar; Clarice Freitas Vilar; Ruy Lyra; Raissa Lyra; Luciana A Naves
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Thyroid autoimmune disorders in patients with acromegaly.

Authors:  M Manavela; C Vigovich; K Danilowicz; A Juri; L Miechi; V Fernandez Valoni; O D Bruno
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

3.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

Review 4.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.

Authors:  Kosma Wolinski; Agata Czarnywojtek; Marek Ruchala
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

5.  Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly.

Authors:  Hee Kyung Kim; Ji Shin Lee; Min Ho Park; Jin Seong Cho; Jee Hee Yoon; Soo Jeong Kim; Ho-Cheol Kang
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

6.  Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable?

Authors:  Jordi L Reverter; Carmen Fajardo; Eugenia Resmini; Isabel Salinas; Mireia Mora; Mariona Llatjós; Gemma Sesmilo; Ferran Rius; Irene Halperin; Susan M Webb; Veronica Ricart; Pedro Riesgo; Dídac Mauricio; Manel Puig-Domingo
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

Review 7.  Challenges in the diagnosis and management of acromegaly: a focus on comorbidities.

Authors:  Alin Abreu; Alejandro Pinzón Tovar; Rafael Castellanos; Alex Valenzuela; Claudia Milena Gómez Giraldo; Alejandro Castellanos Pinedo; Doly Pantoja Guerrero; Carlos Alfonso Builes Barrera; Humberto Ignacio Franco; Antônio Ribeiro-Oliveira; Lucio Vilar; Raquel S Jallad; Felipe Gaia Duarte; Mônica Gadelha; Cesar Luiz Boguszewski; Julio Abucham; Luciana A Naves; Nina Rosa C Musolino; Maria Estela Justamante de Faria; Ciliana Rossato; Marcello D Bronstein
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 8.  Growth Hormone's Effect on Adipose Tissue: Quality versus Quantity.

Authors:  Darlene E Berryman; Edward O List
Journal:  Int J Mol Sci       Date:  2017-07-26       Impact factor: 5.923

9.  A case of a co-secreting TSH and growth hormone pituitary adenoma presenting with a thyroid nodule.

Authors:  Laura Hamilton Adams; Derick Adams
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-08-23

Review 10.  Insulin-Like Growth Factor Pathway and the Thyroid.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.